Belgian Grower Tomerel Increases Light Levels, Decreases Energy Costs Through Fluence LED Retrofit
12.5.2022 15:00:00 EEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its partnership with Tomerel, a tomato grower located in Antwerp, Belgium. Together, the companies retrofitted half of Tomerel’s glasshouse from high-pressure sodium (HPS) fixtures to LEDs, resulting in a 40% increase in light levels while decreasing energy input by 5%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512005116/en/
Tomerel is a multi-generational family farm led by CEO and co-owner Jelle de Ryck—son of founders Els and Eric. Tomerel specializes in glasshouse-grown tomatoes, with a particular focus on cherry tomatoes on the vine. Like many growers in the region, Jelle de Ryck scaled his family’s facility using supplemental HPS fixtures. However, when Jelle sought to maximize the glasshouse’s light output and energy consumption, he turned to Fluence’s advanced LED technology.
“When we set out to identify a partner to assist with our lighting retrofit, we weren’t just looking for lights—we wanted a team that could strategize with us from installation through harvesting. Fluence provided that service and more,” said Jelle.
After installing Fluence’s VYPR 3p top light solution, what were once critical limitations to the farm’s lighting strategy became opportunities to boost yields and reduce energy costs. Traditional HPS fixtures produce excess heat and feature inflexible spectral options. Fluence LEDs, however, run cooler and use a more efficient spectrum. With exploding energy prices in the region, the lightened load on the glasshouse’s HVAC system, in combination with the LEDs’ overall more efficient energy usage, enabled Tomerel to cut its electricity usage while increasing light levels.
“Fluence’s technology drove success for us in multiple ways. The electricity efficiencies enabled us to sell 25% more energy back to the grid and also reduced our gas consumption by 5%. The plants are also thriving under LEDs. We’re seeing improved quality and production throughout the winter months, increases in stem density and improved translocation of sugars throughout the night,” Jelle added.
In close coordination with Fluence’s technical team, Tomerel implemented a PhysioSpec™ DUAL R9B spectral strategy to accommodate plant efficacy. This strategy enabled Tomerel to decrease energy input by 5% even while increasing the amount of light by 40%, ensuring stronger cultivation conditions for Tomerel’s tomato crop. As a result, Tomerel also increased its yield by more than 5% despite the facility receiving 5% less natural light over the winter season. Tomerel also saw an increase in overall fruit weight following the retrofit.
“It is fascinating to see growers like Tomerel make innovative, smart cultivation decisions regarding energy usage,” said Timo Bongartz, general manager for Europe, the Middle East and Africa for Fluence. “The Tomerel team is saving energy wherever possible and also optimizing their facility in such a way to enable them to sell energy back to the grid. And all that without sacrificing plant quality. Fluence is delighted to support Tomerel in running a future-proof glasshouse.”
With Fluence’s technology, the Tomerel team sold 25% more of the glasshouse’s electricity produced by co-generation back to the grid during peak energy prices and saved 5% of its total gas consumption.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005116/en/
Contact information
For Fluence
Emma Chase
pr@fluencebioengineering.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
